Shares of Nextgen Healthcare Inc (NASDAQ:NXGN) have earned a consensus rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $18.50.
A number of equities research analysts have commented on NXGN shares. Zacks Investment Research raised Nextgen Healthcare from a “sell” rating to a “hold” rating in a report on Wednesday, December 5th. TheStreet cut Nextgen Healthcare from a “b-” rating to a “c+” rating in a report on Wednesday, November 21st. Dougherty & Co raised Nextgen Healthcare from a “neutral” rating to a “buy” rating and set a $19.00 price target on the stock in a report on Friday. Cantor Fitzgerald reissued a “buy” rating and set a $23.00 price target on shares of Nextgen Healthcare in a report on Thursday, December 6th. Finally, KeyCorp decreased their price target on Nextgen Healthcare from $17.00 to $16.00 and set an “underweight” rating on the stock in a report on Wednesday, October 31st.
Shares of Nextgen Healthcare stock opened at $16.66 on Friday. Nextgen Healthcare has a one year low of $12.24 and a one year high of $23.73. The firm has a market capitalization of $1.03 billion, a P/E ratio of 29.23, a P/E/G ratio of 3.15 and a beta of 1.07. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.12.
Nextgen Healthcare (NASDAQ:NXGN) last announced its earnings results on Tuesday, October 30th. The company reported $0.24 EPS for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.05. Nextgen Healthcare had a return on equity of 10.23% and a net margin of 1.17%. The company had revenue of $130.30 million for the quarter, compared to analysts’ expectations of $134.55 million. During the same period last year, the firm earned $0.22 EPS. Nextgen Healthcare’s revenue for the quarter was down 1.7% compared to the same quarter last year. As a group, analysts forecast that Nextgen Healthcare will post 0.57 earnings per share for the current year.
Large investors have recently bought and sold shares of the business. Bank of Montreal Can purchased a new position in shares of Nextgen Healthcare during the third quarter valued at about $165,000. BlueMountain Capital Management LLC purchased a new position in shares of Nextgen Healthcare during the third quarter valued at about $205,000. Quantbot Technologies LP purchased a new position in shares of Nextgen Healthcare during the third quarter valued at about $207,000. Hanson & Doremus Investment Management purchased a new position in shares of Nextgen Healthcare during the third quarter valued at about $208,000. Finally, Piedmont Investment Advisors Inc. purchased a new position in shares of Nextgen Healthcare during the third quarter valued at about $222,000. 68.73% of the stock is currently owned by institutional investors and hedge funds.
About Nextgen Healthcare
NextGen Healthcare, Inc provides software, services, and analytics solutions to medical and dental group practices in the United States. The company's principal products include NextGen Enterprise EHR, which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools.
Featured Story: Market Capitalization